Hercules Capital, Inc. (HTGC)
| Market Cap | 3.23B -6.7% |
| Revenue (ttm) | 566.17M +12.3% |
| Net Income | 380.33M +47.7% |
| EPS | 2.01 +32.9% |
| Shares Out | 184.59M |
| PE Ratio | 8.70 |
| Forward PE | 9.06 |
| Dividend | $1.88 (10.73%) |
| Ex-Dividend Date | Aug 11, 2026 |
| Volume | 2,935,993 |
| Open | 17.64 |
| Previous Close | 17.64 |
| Day's Range | 17.51 - 17.74 |
| 52-Week Range | 13.70 - 19.62 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 19.17 (+9.42%) |
| Earnings Date | Jul 30, 2026 |
About HTGC
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management ... [Read more]
Financial Performance
In 2025, Hercules Capital's revenue was $532.49 million, an increase of 7.88% compared to the previous year's $493.59 million. Earnings were $337.03 million, an increase of 29.56%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for HTGC stock is "Buy." The 12-month stock price target is $19.17, which is an increase of 9.42% from the latest price.
News
Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Earnings Call Transcript: Q2 2026
Record Q2 results included all-time highs in investment income and net investment income, with robust originations and strong portfolio credit quality. Liquidity and leverage improved, and the outlook remains positive with expectations for continued strong originations and normalized prepayments.
Hercules Capital Slides: Q2 2026
Hercules Capital has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Hercules Capital Earnings release: Q2 2026
Hercules Capital released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Hercules Capital Quarterly report: Q2 2026
Hercules Capital has published its Q2 2026 quarterly earnings report on July 30, 2026.
Hercules Capital Reports Second Quarter 2026 Financial Results
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an underwritten public offering of $325.0...
Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $325.0...
Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
Hercules Capital Transcript: AGM 2026
The meeting covered strong 2025 and Q1 2026 financial results, record new commitments, and a new supplemental dividend. All six shareholder proposals passed, including director election and plan amendments. The company highlighted its diversified portfolio and conservative balance sheet.
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE N...
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced...
HTGC Lawsuit Alleges CEO Allegedly Certified Misleading Statements - Hercules Capital Investors Face Losses Following CEO Allegedly Certified Misleading Statements: SueWallSt
Important Information Regarding Section 20(a) Individual Liability Claims Against Hercules Capital Officers NEW YORK, May 7, 2026 /PRNewswire/ -- SueWallSt alerts investors in Hercules Capital, Inc. (...
Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), will conduct its 2026 Annual Meeting of Stockholders by virtual meeting on T...
Hercules Capital Earnings Call Transcript: Q1 2026
Record Q1 originations and investment income were achieved amid market volatility, with strong credit quality, robust liquidity, and a balanced portfolio across life sciences and technology. Elevated prepayments from M&A are expected in Q2, supporting continued capital redeployment.
Hercules Capital Slides: Q1 2026
Hercules Capital has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Hercules Capital Earnings release: Q1 2026
Hercules Capital released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Hercules Capital Quarterly report: Q1 2026
Hercules Capital has published its Q1 2026 quarterly earnings report on May 5, 2026.
Hercules Capital Reports First Quarter 2026 Financial Results
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC) th...
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring p...
Hercules Capital Proxy statement: Proxy filing
Hercules Capital filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.